Cartagenia closes US$ 5.9 million (€ 4.25 million) financing round

Boston, MA / Leuven, Belgium: 29 May 2014 - Cartagenia, the leading provider of clinical-grade solutions for genomic assay interpretation and lab reporting to diagnostic genetics labs, clinicians and hospitals, today announced the closing of a $5.9 million (€4.25 million) financing round.

The financing was subscribed by Cartagenia's existing shareholders and management. Shareholders include Capricorn ICT Arkiv, a Leuven-based ICT fund focussing on Digital Healthcare and Big Data, the Flemish investment company PMV and Gemma Frisius Fund, the venture fund of the University of Leuven.

The funds from the financing will be used to expand the company's efforts to commercialize the Cartagenia Bench platform in key markets including North America and Europe. Additionally, the financing will allow Cartagenia to expand its product portfolio in Oncology and Reproductive Health.

More information on the press release or Cartagenia's website. 


Next > Avantium raises € 36M investment from Swire, the Coca-Cola Company, Danone and Alpla

Previous > Avantium selected by Cleantech Group as European cleantech company of the decade.